Beam Therapeutics Inc. (NASDAQ:BEAM) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41. Separately, UBS began covering Beam Therapeutics Inc. (NASDAQ:BEAM) on January 7, 2026, with a $28 price goal and a neutral rating. Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology firm focused on developing a new class of precision genetic drugs.